Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives
08 janv. 2023 13h00 HE
|
Viracta Therapeutics, Inc.
Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC); enrollment into fourth dose...
Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress
30 nov. 2022 18h10 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics Announces New Employment Inducement Grant
21 nov. 2022 17h08 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics Announces New Employment Inducement Grant
14 nov. 2022 16h41 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs
10 nov. 2022 16h05 HE
|
Viracta Therapeutics, Inc.
Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open for enrollment at more than 50 sites worldwide; update on the first indication that may advance from Stage 1 to...
Viracta Therapeutics to Present at Upcoming Investor Conferences
02 nov. 2022 16h05 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated cancers, today announced that company leadership is...
Viracta Therapeutics Announces New Employment Inducement Grant
19 sept. 2022 16h30 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that, in connection...
Viracta and Salubris Announce Equity Financing and Partnership to Bring Novel Treatment for Viral-Associated Cancers to China
04 déc. 2018 01h00 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO and SHENZHEN, China, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Shenzhen Salubris Pharmaceuticals Co. Ltd. (Salubris, SZSE: 002294) and Viracta Therapeutics, Inc. announced the initial closing of a...
Viracta Announces Scientific Advisory Board Formation
25 sept. 2018 08h00 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other...
Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat
11 avr. 2018 08h00 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, April 11, 2018 (GLOBE NEWSWIRE) -- Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious...